Login / Signup

Are sodium-glucose cotransporter-2 inhibitors safe adjunctive drugs during insulin therapy in young children with type 1 diabetes? The first case of type 1 diabetes with SLC5A2 mutation.

Mohamad Ahangar DavoodiMohammad Ali DaneshmandTaraneh Rezaei
Published in: Journal of diabetes (2024)
Highlights A persistent glycosuria alongside hypoglycemia in pediatric type 1 diabetes mellitus needs further evaluation. Morning hypoglycemia is a limiting side effect of sodium glucose transporter 2 (SGLT2) inhibitors in children younger than 5 years old. SLC5A2 mutation functioning as a SGLT2 inhibitor can result in acceptable range of glycated hemoglobin in younger children and lower required doses of insulin.
Keyphrases
  • type diabetes
  • glycemic control
  • young adults
  • insulin resistance
  • weight loss
  • stem cells
  • bone marrow
  • replacement therapy